Akari Therapeutics (AKTX) Change in Account Payables (2014 - 2015)

Akari Therapeutics (AKTX) posted quarterly Change in Account Payables of $333000.0 for Q2 2015, down 66.8% year-on-year from $1.0 million in Q2 2014, and up 147.1% on a QoQ basis from -$707000.0 in Q1 2015.

Akari Therapeutics (AKTX) Change in Account Payables (2014 - 2015) Analysis & Trends

Akari Therapeutics (AKTX) has reported Change in Account Payables for 2 consecutive years, with $333000.0 the latest figure, recorded in Q2 2015.

  • Quarterly Change in Account Payables fell 66.8% year-over-year to $333000.0 in Q2 2015, while the trailing twelve-month figure through Jun 2015 was $245000.0 (changed N/A YoY) and the FY2014 annual result came in at $351000.0, up 133.59% from the prior year.
  • Change in Account Payables improved to $333000.0 in Q2 2015 per AKTX's latest filing, from -$707000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for AKTX reached as high as $1.0 million in Q2 2014 and fell as low as -$707000.0 in Q1 2015.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -42.19 Mn
4 NuCana 279.75 Bn 279.75 Bn - -1.52 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 35.60 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 16.86 Mn
10 Akari Therapeutics 86.55 Mn 86.55 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2015 333,000.00
Jun 30, 2015 333,000.00
Mar 31, 2015 -707,000.00
Mar 31, 2015 -707,000.00
Jun 30, 2014 1.00 Mn
Jun 30, 2014 1.00 Mn
Mar 31, 2014 -384,000.00
Mar 31, 2014 -384,000.00